NORMAL SITUATION

Charlotte De Sutter

Financial year 2025 · closed on 17/02/2025
Net result
-80,6 €
-100.1% YoY
Equity
279,8 k €
-0.0% YoY

Company — Normal situation.

What does Charlotte De Sutter do?

Charlotte De Sutter is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0831.893.774
Legal form
Private company with limited liability
Contributed capital
90 000,00 €
Latest accounts
17/02/2025
Signals
Solid equityGood liquidity
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 15 financial years

202520242023202220212020201920182017201620152014201320122011
Income statement
Gross margin-3,8 k €-4,5 k €-2,9 k €-516,6 €20,8 k €20,7 k €47,8 k €36,7 k €45 k €40,1 k €57,7 k €54,7 k €51,1 k €48,1 k €
EBITDA-3,8 k €-4,6 k €-2,9 k €-726,8 €25,7 k €20,6 k €47,7 k €35,9 k €44,8 k €39,9 k €55,8 k €54,7 k €50,8 k €42,9 k €
Operating result-3,8 k €-4,6 k €-2,9 k €-726,8 €25,7 k €20,6 k €47,7 k €35,9 k €44,7 k €39,7 k €55,5 k €54,5 k €50,6 k €41,6 k €
Net result-80,6 €120,8 k €-12,2 k €-9,7 k €-7,2 k €13,1 k €4,1 k €27 k €-355,5 €4,3 k €4 k €11,1 k €14,6 k €11,1 k €9,2 k €
Balance sheet
Equity279,8 k €279,9 k €159,1 k €171,3 k €181 k €188,2 k €175,1 k €171 k €144 k €144,3 k €140 k €136 k €124,9 k €110,3 k €99,2 k €
Total assets279,9 k €279,9 k €947,3 k €947,7 k €951,4 k €960,1 k €952,6 k €948,7 k €993,9 k €977,4 k €987,6 k €1 M €988,9 k €958,7 k €961,5 k €
Cash279,9 k €279,9 k €57,7 €23,6 €4,2 k €12,9 k €1,2 k €8,4 k €850 €2,5 k €9,1 k €17,4 k €11 k €14,1 k €
Debts46,1 €46,1 €780,8 k €769,8 k €766,1 k €768,8 k €755,4 k €763,5 k €809,5 k €799,7 k €817,2 k €843,6 k €839,8 k €826,1 k €852 k €
Governance

Board of directors

Seen on filing of 17/02/2025 · 1 active · 7 ended

Active mandates

PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Active

Ended mandates

PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
Pierre De Witte

Manager · since 01 novembre 2013 · until 30 septembre 2017

Ended
Annual accounts

Full financial information

202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year17/02/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year2 months12 months12 months12 months12 months12 months
Filing date01/09/202515/07/202519/07/202403/07/202329/08/202230/08/2021
General meeting17/02/202520/06/202521/06/202416/06/202317/06/202218/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

15 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model17/02/202517/02/202501/09/2025DutchPDF
Abridged model31/12/202420/06/202515/07/2025DutchPDF
Abridged model31/12/202321/06/202419/07/2024DutchPDF
Abridged model31/12/202216/06/202303/07/2023DutchPDF
Abridged model31/12/202117/06/202229/08/2022DutchPDF
Abridged model31/12/202018/06/202130/08/2021DutchPDF
Abridged model31/12/201919/06/202025/09/2020DutchPDF
Abridged model31/12/201821/06/201926/08/2019DutchPDF
Abridged model31/12/201715/06/201824/08/2018DutchPDF
Abridged model31/12/201616/06/201729/08/2017DutchPDF
Abridged model31/12/201517/06/201623/08/2016DutchPDF
Abridged model31/12/201419/06/201518/08/2015DutchPDF
Abridged model31/12/201320/06/201429/07/2014DutchPDF
Abridged model31/12/201221/06/201308/08/2013DutchPDF
Abridged model31/12/201115/06/201210/07/2012DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 17/02/2025 · 1 active · 7 ended

Active mandates

PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Active

Ended mandates

PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Director · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
PharmaCross

Manager · since 30 septembre 2017 · 0888.580.475

Represented by Danny Vander Cruyssen

Ended
Pierre De Witte

Manager · since 01 novembre 2013 · until 30 septembre 2017

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Dissolution04/03/2025
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-80,6 €
  2. 2024
    Annual accounts 2024120,8 k €
  3. 2023
    Annual accounts 2023-12,2 k €
  4. 2022
    Annual accounts 2022-9,7 k €
  5. 2021
    Annual accounts 2021-7,2 k €
  6. 2020
    Annual accounts 202013,1 k €
  7. 2019
    Annual accounts 20194,1 k €
  8. 2018
    Annual accounts 201827 k €
  9. 2017
    Annual accounts 2017-355,5 €
  10. 2016
    Annual accounts 20164,3 k €
  11. 2015
    Annual accounts 20154 k €
  12. 2014
    Annual accounts 201411,1 k €
  13. 2013
    Annual accounts 201314,6 k €
  14. 2012
    Annual accounts 201211,1 k €
  15. 2011
    Annual accounts 20119,2 k €